Tempest Therapeutics, Inc. (TPST) has a negative trailing P/E of -0.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -396.78%.
Criteria proven by this page:
Overall SharesGrow Score: 51/100 with 2/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -7.8 | 1.45 | 5.91 | 978.71 | - |
| 2017 | -0.1 | 0.00 | 2.15 | 16.21 | - |
| 2018 | -5.9 | 0.06 | 2.25 | 0.00 | - |
| 2019 | -26.9 | 0.33 | 20.51 | 0.00 | - |
| 2020 | -0.7 | 0.00 | -0.19 | 0.00 | - |
| 2021 | -0.7 | 0.01 | 0.55 | 0.00 | - |
| 2022 | -0.4 | 0.01 | 0.73 | 0.00 | - |
| 2023 | -29.9 | 0.75 | 32.94 | 0.00 | - |
| 2024 | -7.2 | 0.34 | 15.83 | 0.00 | - |
| 2025 | -0.5 | 0.00 | 1.79 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-575.73 | $653K | $-82.26M | -12597.2% |
| 2017 | $-72,406.30 | $295K | $-84.58M | -28670.5% |
| 2018 | $-263.65 | $0.00 | $-27.19M | - |
| 2019 | $-48.77 | $0.00 | $-44.57M | - |
| 2020 | $-612.56 | $0.00 | $-19.12M | - |
| 2021 | $-7.80 | $0.00 | $-28.3M | - |
| 2022 | $-3.18 | $0.00 | $-35.71M | - |
| 2023 | $-1.91 | $0.00 | $-29.49M | - |
| 2024 | $-1.50 | $0.00 | $-41.84M | - |
| 2025 | $-6.33 | $0.00 | $-26.26M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-2.76 | $-2.76 – $-2.76 | $17.85M | $17.85M – $17.85M | 1 |
| 2027 | $-2.28 | $-2.28 – $-2.28 | $57.82M | $57.82M – $57.82M | 1 |
| 2028 | $-2.13 | $-2.13 – $-2.13 | $4.3M | $4.3M – $4.3M | 1 |
| 2029 | $-4.23 | $-4.23 – $-4.23 | $117.7M | $117.7M – $117.7M | 1 |
